| 产品名称 | Peptides EP07860_1 | gp100 209-217 mutant (HLA-A*02:01) 210M |
|---|---|
| 目录号 | EP07860_1 |
| 别名 | gp100 209-217 mutant (HLA-A*02:01) 210M |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP07860_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP07860_1 | gp100 209-217 mutant (HLA-A*02:01) 210M
品名：gp100 209-217 mutant (HLA-A*02:01) 210M
货号：EP07860_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human). This epitope has been studied for immune reactivity in several publication, tested in T cell assays and MHC ligand assays. This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the gp100 209-217 peptide to gp100 209-217 Met2 at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100
| Protein | Melanocyte protein PMEL |
| Species | Human |
| Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication | Cancer |
